Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Nagoya
Clinical trial register · Japan

Clinical Trials in Nagoya, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Nagoya 23 Kashiwa-shi 18 Fukuoka 16 Yokohama 14 Sapporo 13
Narrow the registerReset
Recruitment status
Phase
Site location
Nagoya23 Kashiwa-shi18 Fukuoka16 Yokohama14 Sapporo13
All 92 locations
Target enrolment
to

Trials with a site in Nagoya

23 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Amgen
Phase 3
304
Nagoya, Meguro-ku, Ube, Tokyo
2026-05-27
Recruiting
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
NCT07403721Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen
Phase 1
464
Nagoya, Kashiwa-shi, Chuo-ku, Koto-ku
2026-04-08
Recruiting
Amgen
Phase 3
750
Nagoya, Matsuyama, Fukuoka, Kobe, Kanazawa, Kita-gun, Sagamihara-shi, Osaka
2025-11-28
Recruiting
Amgen
Phase 1
434
Nagoya, Kashiwa-shi, Chuo-ku
2025-07-31
Recruiting
Amgen
Phase 3
12,800
Nagoya, Toyoake-shi, Chiba, Sapporo, Naka, Toride-shi, Tsuchiura-shi, Kanazawa
2025-07-25
Active, closed
Amgen
Phase 3
279
Nagoya, Fukuoka, Onga-gun, Hashima-gun, Sapporo, Amagasaki-shi, Kobe, Naka
2025-06-13
Recruiting
Amgen
Phase 3
844
Nagoya-shi, Nagoya, Sapporo, Kita Kyushu-shi, Tsukuba, Kahoku, Kanazawa, Yokohama
2025-02-25
Active, closed
Amgen
Phase 2
61
Nagoya, Kashiwa-shi, Sunto-gun, Chuo-ku, Koto-ku, Wakayama
2024-12-26
Active, closed
Amgen
Phase 3
707
Nagoya, Kashiwa-shi, Matsuyama, Maebashi, Sapporo, Kanazawa, Sagamihara-shi, Yokohama
2024-12-09
Active, closed
Amgen
Phase 1
49
Nagoya, Kashiwa-shi, Sunto-gun, Wakayama
2024-09-17
Active, closed
Amgen
Phase 3
315
Nagoya, Funabashi-shi, Fukuoka, Iizuka-shi, Maebashi, Fukuyama, Hiroshima, Asahikawa
2024-09-09
Recruiting
Amgen
Phase 3
450
Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Akashi-shi, Kawasaki-shi
2024-07-17
Active, closed
Amgen
Phase 3
563
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Kurume-shi, Sapporo, Akashi-shi, Yokohama
2024-06-05
Active, closed
Amgen
Phase 3
434
Nagoya, Sapporo, Kita Kyushu-shi, Nishinomiya-Shi, Tsukuba, Kahoku, Kanazawa, Yokohama
2024-04-08
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Amgen
Phase 3
404
Nagoya, Kashiwa-shi, Matsuyama, Kurume-shi, Sapporo, Yokohama, Sendai, Niigata
2024-02-20
Recruiting
Amgen
Phase 3
750
Nagoya, Hirosaki-shi, Chiba, Kashiwa-shi, Matsuyama, Toon-shi, Fukuoka, Kitakyushu-shi
2023-11-16
Active, closed
Amgen
Phase 3
509
Nagoya, Kashiwa-shi, Matsuyama, Kurume-shi, Sapporo, Akashi-shi, Yokohama, Sendai
2023-05-31
Active, closed
Amgen
Phase 3
7,297
Kasugai-shi, Nagoya, Seto-shi, Toyoake-shi, Hirosaki-shi, Asahi-shi, Matsudo-shi, Yoshida-gun
2022-12-14
Active, closed
Amgen
Phase 1/2
329
Nagoya, Kashiwa-shi, Chuo-ku
2022-02-01
Active, closed
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
NCT05060016Relapsed/Refractory Small Cell Lung Cancer
Amgen
Phase 2
222
Nagoya, Kashiwa-shi, Okayama, Osakasayama-shi, Sunto-gun, Koto-ku, Wakayama
2021-12-01
Active, closed
Amgen
Phase 3
303
Nagoya, Akita, Kamogawa-shi, Yoshida-gun, Fukuoka, Kurume-shi, Fukushima, Maebashi
2021-11-02
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Amgen
Phase 1
610
Nagoya, Kashiwa-shi, Koto-ku
2019-12-17
Rows per page Showing 1–23 of 23
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 October 2026. https://priyalifescience.com/clinical-trials-japan/city/nagoya

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 23 of those studies with a site in Nagoya that also match the filters currently applied.

How many clinical trials are recruiting in Nagoya?

8 of the 23 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nagoya), 23 studies
PhaseStudiesRecruitingShare
Phase 315665.2%
Phase 15221.7%
Phase 2208.7%
Phase 1/2104.3%

Most active sponsors

Lead sponsors with the most studies (Nagoya)
Lead sponsorStudiesRecruiting
Amgen238
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.